Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 8/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622131 | 0.98 | CSNK2A1 (0.43) | CSNK2A1PDE4AMCHR1PDE4DPDE4B | |
| SCHEMBL30612831 | 0.96 | CSNK2A1 (0.41) | CSNK2A1PDE4AMCHR1PDE4DPDE4B | |
| SCHEMBL10188238 | 0.96 | CSNK2A1 (0.41) | CSNK2A1PDE4AMCHR1PDE4DPDE4B | |
| SCHEMBL22042173 | 0.93 | CSNK2A1 (0.36) | CSNK2A1PDE4A | |
| SCHEMBL2252843 | 0.85 | HTR1A (0.51) | — | |
| SCHEMBL3022887 | 0.82 | HRH3 (0.43) | — | |
| SCHEMBL13419689 | 0.81 | HTR2C (0.44) | — | |
| SCHEMBL14054027 | 0.81 | SLC6A2 (0.51) | — | |
| SCHEMBL10012300 | 0.80 | CSNK2A1 (0.45) | CSNK2A1PDE4AMCHR1PDE4DPDE4B | |
| SCHEMBL26144164 | 0.80 | CSNK2A1 (0.41) | CSNK2A1PDE4AMCHR1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-20250214976-A1 | GPR35 MODULATORS AND USES THEREOF | CROSSIGNAL THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4551571-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790050-A | Oxazole TRPML1 agonists and uses thereof | 利布拉医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-4504712-A1 | GPR35 MODULATORS AND USES THEREOF | Crossignal Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119137105-A | GPR35 modulators and uses thereof | 交信医药研发公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12098145-B2 | Oxazole TRPML1 agonists and uses thereof | LIBRA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-20240158381-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024011155-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2678334-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2627651-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| CN-103153988-A | Antiviral compounds | ABBVIE INC | 2013-06-12 | — | — | CN | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116257-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214976-A1 | GPR35 MODULATORS AND USES THEREOF | GPR35, GPR34, GPR68 | CSNK2A1 1165/4885PDE4A 2314/4885MCHR1 656/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CSNK2A1 3275/4885PDE4A 3090/4885MCHR1 4556/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CSNK2A1 3275/4885PDE4A 3090/4885MCHR1 4556/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CSNK2A1 3275/4885PDE4A 3090/4885MCHR1 4556/4885 |
| US-12098145-B2 | Oxazole TRPML1 agonists and uses thereof | TRPM7, TRPM2, TRPM5 | CSNK2A1 2437/4885PDE4A 1186/4885MCHR1 848/4885 |
| US-20240158381-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | TRPM7, TRPM2, TRPM5 | CSNK2A1 2344/4885PDE4A 1828/4885MCHR1 1444/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CSNK2A1 3275/4885PDE4A 3090/4885MCHR1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.